Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in Netherton Syndrome
CTR20231690Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of spesolimab in Netherton syndrome (NS), sponsored by Boehringer Ingelheim. Started Jun 2023; status: terminated.
02
Drugs
spesolimab
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on CTR20231690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231690.